ALS関連

Ⅰ 英文原著

  1. Aizawa H, Nagumo S, Hideyama T, Kato H, Kwak S, Terashi H, Suzuki Y, Kimura T.: Morphometric analysis of spinal motor neuron degeneration in sporadic amyotrophic lateral sclerosis. J Neurol Sci. 2024 Sep 15;464:123177.doi: 10.1016/j.jns.2024.123177Epub 2024 Aug 12.
  2. Hideyama T, Teramoto S, Kato H, Terashi H, Kwak S, Aizawa H.: Negative features of sporadic amyotrophic lateral sclerosis: Motor neurons of Onuf's nucleus survive in ADAR2-conditional knockout mice.J Neurol Sci. 2024 Aug 15;463:123142.doi: 10.1016/j.jns.2024.123142Epub 2024 Jul 15.
  3. Hosaka T, Tsuji H, Terada M, Tomidokoro Y, Ishii A, Nakamagoe K, Ishii K, Terashi H, Aizawa H, Tamaoka A, Kwak S.: Glutamine/arginine site-unedited GluA2 mRNA in cerebrospinal fluid as a biomarker for amyotrophic lateral sclerosis.J Neurol Neurosurg Psychiatry. 2023 Oct;94(10):876-878.doi: 10.1136/jnnp-2023-331164Epub 2023 May 3.
  4. Kato H, Naito M, Saito T, Hideyama T, Terashi H, Kwak S, Aizawa H.: Effect of Serum Perampanel Concentration on Sporadic Amyotrophic Lateral Sclerosis Progression. J Clin Neurol.2023 May;19(3):280-287.doi: 10.3988/jcn.2022.0213Epub 2023 Mar 13.
  5. Naito M, Hideyama T, Teramoto S, Saito T, Kato H, Terashi H, Kwak S, Aizawa H.: Pathological features of glial cells and motor neurons in the anterior horn of the spinal cord in sporadic ALS using ADAR2 conditional knockout mice. J Neurol Sci.2023 Jan 15;444:120520.doi: 10.1016/j.jns.2022.120520Epub 2022 Dec 9.
  6. Kato H, Naito M, Saito T, Hideyama T, Suzuki Y, Kimura T, Kwak S, Aizawa H.: Prolyl Isomerase Pin1 Expression in the Spinal Motor Neurons of Patients With Sporadic Amyotrophic Lateral Sclerosis. J Clin Neurol. 2022 Jul;18(4):463-469.doi: 10.3988/jcn.2022.18.4.463
  7. Aizawa H, Teramoto S, Hideyama T, Kato H, Terashi H, Suzuki Y, Kimura T, Kwak S.: Nuclear pore destruction and loss of nuclear TDP-43 in FUS mutation-related amyotrophic lateral sclerosis motor neurons. J Neurol Sci.2022 May 15;436:120187.doi: 10.1016/j.jns.2022.120187Epub 2022 Feb 16.
  8. Aizawa H, Kato H, Oba K, Kawahara T, Okubo Y, Saito T, Naito M, Urushitani M, Tamaoka A, Nakamagoe K, Ishii K, Kanda T, Katsuno M, Atsuta N, Maeda Y, Nagai M, Nishiyama K, Ishiura H, Toda T, Kawata A, Abe K, Yabe I, Takahashi-Iwata I, Sasaki H, Warita H, Aoki M, Sobue G, Mizusawa H, Matsuyama Y, Haga T, Kwak S.:Randomized phase 2 study of perampanel for sporadic amyotrophic lateral sclerosis. J Neurol.2022 Feb;269(2):885-896.doi: 10.1007/s00415-021-10670-yEpub 2021 Jun 30.
  9. Akamatsu M, Yamashita T, Teramoto S, Huang Z, Lynch J, Toda T, Niu L, Kwak S.: Testing of the therapeutic efficacy and safety of AMPA receptor RNA aptamers in an ALS mouse model.Life Sci Alliance.2022 Jan 12;5(4):e202101193.doi: 10.26508/lsa.202101193Print 2022 Apr.
  10. Aizawa H, Yamashita T, Kato H, Kimura T,Kwak S.: Impaired Nucleoporins Are Present in Sporadic Amyotrophic Lateral Sclerosis Motor Neurons that Exhibit Mislocalization of the 43-kDa TAR DNA-Binding Protein. J Clin Neurol.2019.1. 15(1):62-67.doi:10.3988/jcn.2019.15.1.62
  11. Takahira Shirahase,Yoshihisa Watanabe,Atsushi Tsujimura,Shin Kwak,Toshiro Yamamoto,Narisato Kanamura and Masaki Tanaka: Ethanol Preference and Drinking Behavior Are Controlled by RNA Editing in the Nucleus Accumbens. Front.Behav.Neurosci. 2019.1.15.doi:10.1.10.3389/fnbeh.2018.00331
  12. Hosaka T, Yamashita T, Teramoto S, Hirose N, Tamaoka A, Kwak S.: ADAR2-dependent A-to-I RNA editing in the extracellular linear and circular RNAs. Neurosci Res 2018.11.16. pii: S0168-0102(18)30587-X.doi: 10.1016/j.neures.2018.11.005.
  13. Yamashita T, Kwak S:Cell death cascade and molecular therapy in ADAR2-deficient motor neurons of ALS.Neurosci Res 2019 Jul;144:4-13. doi:10.1016/j.neures.2018.06.004.
  14. Takenari Yamashita, Hitoshi Aizawa, Sayaka Teramoto, Megumi Akamatsu & Shin Kwak: Calpain-dependent disruption of nucleo-cytoplasmic transport in ALS motor neurons. Scientific Reports 7:39994,2017.1.3.doi: 10.1038/srep39994.
  15. Akamatsu M, Yamashita T, Hirose N, Teramoto S, Kwak S: The AMPA receptor antagonist perampanel robustly rescues amyotrophic lateral sclerosis (ALS) pathology in sporadic ALS model mice. Scientific Reports 7:28649,2016.6.28.doi:10.1038/srep28649.
  16. Aizawa H, Hideyama T, Yamashita T, Kimura T, Suzuki N, Aoki M, Kwak S: Deficient RNA-editing enzyme ADAR2 in an amyotrophic lateral sclerosis patient with a FUSP525L mutation. Journal of Clinical Neuroscience 32: 128-129, 2016.6.21.doi:10.1016/j.jocn.2015.12.039.
  17. Yamashita T, Teramoto S, Kwak S: Phosphorylated TDP-43 becomes resistant to cleavage by calpain: a regulatory role for phosphorylation in TDP-43 pathology of ALS/FTLD. Neuroscience Research 107:63-69,2016.6.1. doi:10.1016/j.neures.2015.12.006.
  18. Sasaki S, Yamashita T, Kwak S: Autophagy in spinal motor neurons of conditional ADAR2-knockout mice: an implication for a role of calcium in increased autophagy flux in ALS. Neuroscience Letters 598:79-84,2015. doi:10.1016/j.neulet.2015.05.025.(Corrigendum 602:173,2015)
  19. Yamashita T, Kwak S：The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients. Journal of Brain Research 1585:28-38,2014/10.10. doi.org/10.1016/j.brainres.2013.12.011.
  20. Sasaki S, Yamashita T, Hideyama T, Kwak S: Unique nuclear vacuoles in the motor neurons of conditional ADAR2-knockout mice. Journal of Brain Research 1550:536-546,2014.3.6.doi: 10.1016/j.brainres.2014.01.006.
  21. Akamatsu M, Takuma H, Yamashita T, Okada T, Keino-Masu K, Ishii K, Kwak S, Masu M, Tamaoka A: A unique mouse model for investigating the properties of amyotrophic lateral sclerosis-associated protein TDP-43, by in utero electroporation. Neuroscience Research 77(4):234-41,2013. doi:10.1016/j.neures.2013.09.009
  22. Yamashita T, Chai HL, Teramoto S, Tsuji S, Shimazaki K, Muramatsu S, Kwak S: Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9-ADAR2 delivery to motor neurons. EMBO Molecular Medicine 5(11):171,2013.2013.9.24.doi:10.1002/emmm.201302935.
  23. Al-Chalabi A, Kwak S, Mehler M, Rouleau G, Siddique T, Strong M, Leigh PN: Genetic and epigenetic studies of amhyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener 14 (Supple 1) 44-52, 2013. doi: 10.3109/21678421.2013.778571.
  24. Shin Kwak: Molecular Link between Inefficient GluA2 RNA Editing and TDP-43 Pathology in ALS Motor Neurons. Brain and Nerve 64:5,549-556,2012
  25. Yamashita T, Hideyama T, Hachiga K, Teramoto S, Takano J, Iwata N, Saido TC, and  Kwak S: A role for calpain-dependent cleavage of TDP-43 in amyotrophic lateral sclerosis pathology. Nature Communications 3:1307,2012. doi:10.1038/ncomms2303,2012
  26. Hideyama T, Teramoto S, Hachiga K, Yamashita T, Kwak S: Co-occurrence of TDP-43 mislocalization with reduced RNA editing enzyme, ADAR2, in aged mouse motor neurons: implications for age-related acceleration of ALS. PLoSOne 7(8):e43469, 2012.10.1371/journal.pone.0043469 .
  27. Yamashita T, Hideyama T, Teramoto S, Kwak S: Abnormal processing of TDP-43 does not regulate ADAR2 activity in cultured cell lines. Neuroscience Research 73: 153-160, 2012.doi:10.1016/j.neures.2012.02.015.
  28. Yamashita T, Tadami C, Nishimoto Y, Hideyama T, Kimura D, Suzuki T, Kwak S: RNA editing of the Q/R site of GluA2 in different cultured cell lines that constitutively express different levels of RNA editing enzyme ADAR2.Neuroscience Research 73: 42-48, 2012.doi:10.1016/j.neures.2012.02.002.
  29. Hideyama T, Yamashita T, Aizawa H, Tsuji S, Kakita A, Takahashi H, Kwak S: Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons. Neurobiology of Disease 45:1121-28, 2012. doi:10.1016/j.nbd.2011.12.033
  30. Hideyama T, Kwak S: When does ALS start? ADAR2-GluA2 hypothesis for the etiology of sporadic ALS. Frontier MolecularNeuroscience 4:33, 2011. doi:10.3389/fnmol.2011.00033
  31. Kwak S, Hideyama T, Yamashita T, Aizawa H: AMPA receptor-mediated neuronal death in sporadic ALS. Neuropathology 30:182-188,2010,
  32. Hideyama T, Yamashita T, Suzuki T, Tsuji S, Higuchi M, Seeburg PH, Takahashi R, Misawa H, Kwak S: Induced loss of ADAR2 engenders slow death of motor neurons from Q/R site-unedited GluR2. The Journal of Neuroscience 30: 11917-11925, 2010. doi:10.1523/JNEUROSCI.2021-10.2010.
  33. Aizawa H, Sawada J, Hideyama T, Yamashita T, Katayama T, Hasebe N, KimuraT, Yahara O, Kwak S: TDP-43 pathology in sporadic ALS occurs in motor neurons lacking RNA editing enzyme ADAR2. Acta Neuropathologica 120: 75-84, 2010.doi:10.1007/s00401-010-0678-x.
  34. Sawada J, Yamashita T (contributed equally with JS), Aizawa H, Aburakawa Y, Hasebe N, Kwak S: Effects of antidepressants on GluR2 Q/R site-RNA editing in a modified HeLa cell line. Neuroscience Research 64:251-258, 2009. doi:10.1016/j.neures.2009.03.009.
  35. Nishimoto Y, Yamashita T (contributed equally with YN), Hideyama T, Tsuji S, Suzuki N, Kwak S: Determination of editors of mRNAs with site-selective A-to-I editing positions. Neuroscience Research 61: 201-206, 2008. doi:10.1016/j.neures.2008.02.009
  36. Iwata NK, Aoki S, Okabe S, Arai N, Terao Y, Kwak S, Abe O, Kanazawa I,Tsuji S, Ugawa Y: Evaluation of corticospinal tracts in ALS with diffusion tensor MRI and brainstem stimulation. Neurology 70: 528-32, 2008. doi:10.1212/01.wnl.0000299186.72374.19
  37. Hideyama T, Momose T, Shimizu J, Tsuji S, Kwak S: A PET study on the role of nigral lesions in parkinsonism in patients with ALS. Arch Neurol 63:1719-1722, 2006.doi:10.1001/archneur.63.12.1719
  38. Sun H, Kawahara Y, Ito K, Kanazawa I, Kwak S: Slow and selective death of spinal motor neurons in vivo by intrathecal infusion of kainic acid: implications for AMPA receptor-mediated excitotoxicity in ALS. Journal of Neurochemistry 98:782-791, 2006.doi:0.1111/j.1471-4159.2006.03903.x
  39. Kawahara Y, Sun H, Ito K, Hideyama T, Aoki M, Sobue G, Tsuji S, Kwak S: Underediting of GluR2 mRNA, a neuronal death inducing molecular change in sporadic ALS, does not occur in motor neurons in SBMA patients or SOD1 transgenic rats. Neuroscience Research 54:11-15, 2006. doi:10.1016/j.neures.2005.09.006.
  40. Kawahara Y, Ito K, Ito M, Tsuji S, Kwak S: Novel splice variants of human ADAR2 mRNA: skipping of the exon encoding the dsRNA-binding domains, and multiple C-terminal splice sites. Gene 363: 193-201, 2005. doi:10.1016/j.gene.2005.07.028
  41. Yamamoto Y, Struzik ZR, Soma R, Ohashi K, Kwak S: Noisy vestibular stimulation improves autonomic and motor responsiveness in central neuro-degenerative disorders. Annals of Neurology 58: 175-181, 2005. doi:10.1002/ana.20574
  42. Aoki S, Iwata NK, Masutani Y, Yoshida M, Abe O, Ugawa Y, Masumoto T, Mori H, Hayashi N, Kabasawa H, Kwak S, Takahashi S, Tsuji S, Ohtomo K: Quantitative evaluation of the pyramidal tract segmented by diffusion tensor tractography: feasibility study in patients with amyotrophic lateral sclerosis. Radiation Medicine 23: 195-199, 2005. https://www.ncbi.nlm.nih.gov/pubmed/15940067
  43. Sun H, Kawahara Y, Ito K, Kanazawa I, Kwak S: Expression profile of AMPA receptor subunit mRNA in single adult rat brain and spinal cord neurons in situ. Neuroscience Research 52:228-234, 2005.doi:10.1016/j.neures.2005.03.008.
  44. Kawahara Y, Ito K, Sun H, Ito M, Kanazawa I, Kwak S: GluR4c, an alternative splicing isoform of GluR4 is abundantly expressed in adult human brain. Molecular Journal of Brain Research 127：150-155, 2004.doi:10.1016/j.molbrainres.2004.05.020.
  45. Kawahara Y, Ito K, Sun H, Aizawa H, Kanazawa I, Kwak S: RNA editing and death of motor neurons. Nature 427:801, 2004.doi:10.1038/427801a.
  46. Kawahara Y, Ito K, Sun H, Ito M, Kanazawa I, Kwak S: Regulation of glutamate receptor RNA editing and ADAR mRNA expression in developing human normal and Down’s syndrome brains. Developmental Journal of Brain Research 148：151-155, 2004. doi:10.1016/j.devbrainres.2003.11.008.
  47. Kawahara Y, Ito K, Sun H, Kanazawa I, Kwak S: Low editing efficiency of GluR2 mRNA is associated with a low relative abundance of ADAR2 mRNA in white matter of normal human brain. European Journal of Neuroscience 18:23-33, 2003. doi:10.1046/j.1460-9568.2003.02718.x.
  48. Kawahara Y, Kwak S, Sun H, Ito K, Hashida H, Aizawa H, Jeong S-Y, Kanazawa I: Human spinal motoneurons express low relative abundance of GluR2 mRNA: An implication for excitotoxicity in ALS. Jornal of Neurochemistry 85:680-689, 2003.doi:10.1046/j.1471-4159.2003.01703.x.
  49. Takuma H, Kwak S, Yoshizawa T, Kanazawa I: Reduction of GluR2 RNA editing, a molecular change that increases calcium influx through AMPA receptors,selective in the spinal ventral gray of patients with amyotrophic lateral sclerosis. Annals of Neurology 46:806-815, 1999.
このページの先頭へ

Ⅱ 英文総説

  1. Hosaka T, Tsuji H, Kwak S.:Roles of Aging, Circular RNAs, and RNA Editing in the Pathogenesis of Amyotrophic Lateral Sclerosis: Potential Biomarkers and Therapeutic Targets.cells. 2023.5.22, 12(10):1443,doi: 10.3390/cells12101443.
  2. Hosaka T, Tsuji H, Kwak S.:RNA Editing: A New Therapeutic Target in Amyotrophic Lateral Sclerosis and Other Neurological Diseases.Int J Mol Sci. 2021.10.11, 22(20):10958,doi: 10.3390/ijms222010958.
  3. Hosaka T, Yamashita T, Tamaoka A, Kwak S.:Extracellular RNAs as Biomarkers of Sporadic Amyotrophic Lateral Sclerosis and Other Neurodegenerative Diseases.Int J Mol Sci.2019.6.27, 20(13):3148, doi: 10.3390/ijms20133148.
  4. Yamashita T, Kwak S：Cell death cascade and molecular therapy in ADAR2-deficient motor neurons of ALS.Neuroscience Research 2018 Jun 23. pii: S0168-0102(18)30200-1.doi:.https://doi.org/10.1016/j.neures.2018.06.004
  5. Yamashita T, Akamatsu M, Kwak S：Altered intracellular milieu of ADAR2-deficient motor neurons in amyotrophic lateral sclerosis.Genes 8-2:60,2017.2.8.doi:10.3390/genes 8020060.
  6. Yamashita T, Kwak S: The molecular link between inefficient GluA2 Q/R site-RNA editing and TDP-43 pathology in motor neurons of sporadic amyotrophic lateral sclerosis patients.Journal of Brain Research. 1584:28-38, 2014. doi:10.1016/j.brainres.2013.12.011.
  7. Kwak S, Hideyama T, Yamashita T, Aizawa H: AMPA receptor-mediated neuronal death in sporadic ALS. Neuropathology 30:182-188, 2010. doi:10.1111/j.1440-1789.2009.01090.x.
  8. Hideyama T, Yamashita T, Nishimoto Y, Suzuki T, Kwak S: Novel etiologic and therapeutic strategies for neurodiseases: RNA editing enzyme abnormality in sporadic amyotrophic lateral sclerosis. Journal of Pharmacological Sciences, 113:9-13, 2010. https://www.ncbi.nlm.nih.gov/pubmed/20424386
  9. Kwak S, Nishimoto Y, Yamashita T: Newly identified ADAR2-mediated editing positions as a useful tool for ALS research. RNA Biology 5:193-197, 2008.
  10. Buckingham SD, Kwak S, Jones AK, Blackshaw SE, Sattelle DB: Edited GluR2, a gatekeeper for motor neuron survival? Bio Essays 30:1185-1192, 2008. doi:10.1002/bies.20836.
  11. Kwak S, Hideyama T, Yamashita T: AMPA receptor-mediated neuronal death in motor neuron diseases. In: Amino Acid Receptor Research, Eds. Paley BF, Warfield TE, Nova Science Publishers Inc. NY. pp 293-310, 2008.
  12. Kwak S, Weiss JH: Calcium permeable AMPA channel in neurodegenerative disease and ischemia. Curr Opin Neurobiol, 16:281-287, 2006.
  13. Kawahara Y, Kwak S: Excitotoxicity and ALS: what is unique about the AMPA receptors expressed on spinal motor neurons? Amyotroph Lateral Scler Other Motor Neuron Disord, 6:131-144, 2005.
  14. Kwak S, Kawahara Y: Deficient RNA editing of GluR2 and neuronal death in ALS.　Journal of Molecular Medicine, 83:110-120, 2005.
  15. Kwak S, Takuma H, Kanazawa I: Molecular changes of AMPA receptor subunits in ALS spinal cord. In Molecular Mechanism and Therapeutics of Amyotrophic Lateral Sclerosis. Ed. Abe K, Elsevier Science BV, Amsterdam, pp197-202, 2001.
このページの先頭へ

Ⅲ 和文総説

  1. 保坂孝史, 郭　伸：筋萎縮性側索硬化症―RNAメタポリズムの観点からみたバイオマーカーおよび治療の開発. 医学のあゆみ, 第273巻第1号：50-56, 2020.4.
  2. 郭　伸：C．遺伝子治療各論 ALS. Clinical Neuroscience, 38：354-358, 2020.3.
  3. 相澤仁志、郭　伸：孤発性ALSに対するぺランパネル. BRAIN and NERVE, 71：1270-1278, 2019.11. doi:10.11477/mf.1416201437
  4. 郭　伸：特異的にカルシウム透過性AMPA受容体に作用するRNAアプタマーによるALSの分子標的治療法の開発. JALSA, 106：16-17, 2018.12.
  5. 赤松 恵, 山下雄也, 郭　伸：孤発性ALSの病態と治療－AMPA受容体阻害薬による筋萎縮性側索硬化症治療の可能性―. 神経治療学, 34-2：86-94, 2017.
  6. 郭　伸：孤発性ALSに対する遺伝子治療法の開発. 臨床評価, 44.3：588-593, 2016.12.
  7. 郭　伸：筋委縮性側索硬化症(ALS)とその治療. ヒトの動きの神経科学シリーズ・Ⅲ　筋力発揮の脳・神経科学－その基礎から臨床まで－：市村出版.168-185,2017.
  8. 山下雄也, 郭　伸：神経疾患とRNA編集異常－孤発性ALSの分子病態モデルマウスを用いたALSの治療法開発.[Abnormal RNA editing and treatment strategy in neurological diseases; towards cure for ALS.] 生化学, 88.5：600-608,2016.10.26. doi:10.14952/SEIKAGAKU.2016.880600
  9. 山下雄也, 郭　伸：ALSの遺伝子治療 分子病態解明から治療へ. 生体の科学, 67.45：323-328, 2016.8.1.
  10. 山下雄也, 郭　伸：筋萎縮性側索硬化症－孤発性ALSモデルマウスを用いたALSの遺伝子治療法開発－. 遺伝子医学 MOOK, 30：257-263,2016.6.20.
  11. 山下雄也, 郭　伸：TDP-43病理形成メカニズムにおけるTDP-43のカルパイン依存性断片化の意義. 臨床神経学, 54：1151-1154,2014.
  12. 山下雄也, 郭　伸：TDP-43病理形成メカニズム. Dementia Japan, 28：307-318,2014.
  13. 日出山拓人, 郭　伸：ALS医療 ALSに対する治療方法の開発, 日本プランニングセンター, 難病と在宅ケア, Vol.No18, 2013.
  14. 山下雄也, 郭　伸：RNA editingと筋萎縮性側索硬化症. RNA　Biologyからみた神経変性疾患の病態機序. 医学のあゆみ, 医歯薬出版, 東京, 247：412-420, 2013.11.2
  15. 郭　伸: グルタミン酸受容体のRNA編集異常.すべてがわかるALS・運動ニューロン疾患, シリーズ＜アクチュアル脳・神経疾患の臨床＞　総編集　辻省次, 専門編集　祖父江元, 中山書店　東京, 204-213，2013.
  16. 日出山拓人, 郭　伸：ADAR2発現低下と孤発性ALS. 脳 21-15,34-40，2012
  17. 日出山拓人, 郭　伸：筋萎縮性側索硬化症（ALS）, 運動ニューロン疾患. 神経疾患. 最新の治療2012-2014：243-246，2012.
  18. 郭　伸：RNA editing活性低下とTDP-43病理孤発性ALS運動ニューロンにおける疾患特異的両分子異常の分子連関. Brain and Nerve 64(5)549-556，2012.
  19. 日出山拓人, 郭　伸：興奮毒性とAMPA受容体編集異常. Clinical Neuroscience 29:1011-1014， 2011.
  20. 日出山拓人, 郭　伸：孤発性ALS患者運動ニューロンに見出された分子病態RNA editing異常に基づいたモデルマウスの開発. 医学のあゆみ, 医歯薬出版, 東京, 235：246-250，2010
  21. 日出山拓人, 山下雄也, 郭　伸：グルタミン酸受容体と孤発性筋萎縮性側索硬化症. 実験医学 28：109-117，2010.
  22. 日出山拓人, 郭　伸：ALSにおけるRNA editing異常. Clinical Neuroscience 28:246-7，2010.
  23. 日出山拓人, 郭　伸：孤発性ALSと興奮性アミノ酸. Clinical Neuroscience 26:303-305，2008.
  24. 相澤仁志, 郭　伸：ALSと興奮性アミノ酸. Brain and Nerve 59:1117-1127，2007.
  25. 日出山拓人, 郭　伸：孤発性ALSの病因. 難病と在宅ケア 13:7-10，2007.
  26. 郭　伸：ALSの運動ニューロン死とグルタミン酸受容体の分子変化. 神経進歩 50:902-911，2006.
  27. 西本祥仁, 日出山拓人, 河原行郎, 郭　伸：AMPA受容体サブユニットGluR2 のRNA編集とALSにおける神経細胞死. Clinical Neuroscience24：222-225，2006.
  28. 西本祥仁, 日出山拓人, 河原行郎, 郭　伸ALSにおける分子生物学的変化--GluR2 RNA編集率の低下--.医学の歩み 215：683-687，2005.
  29. 西本祥仁, 日出山拓人, 郭　伸：グルタミン酸受容体, イオノトロピック, AMPA２（GRIA2）. 生体の科学 56：424-425，2005.
  30. 西本祥仁, 日出山拓人, 郭　伸：脳卒中における興奮性アミノ酸毒性. カレントテラピー 23：94-95，2005.
  31. 日出山拓人, 河原行郎, 郭　伸：ALSの分子生物学. Current Insights in Neurological Science　13：2-3，2005.
  32. 日出山拓人, 河原行郎, 郭　伸：筋萎縮性側索硬化症の分子病理?病態と治療?　最新医学 60：1072-1080，2005.
  33. 日出山拓人, 河原行郎, 郭　伸：ALSとAMPA受容体. 脳神経 57：585-598，2005.
  34. 日出山拓人, 河原行郎, 郭　伸：筋萎縮性側索硬化症の研究の進歩. 医学の歩み 212：937-944，2005.
  35. 日出山拓人, 河原行郎, 郭　伸：筋萎縮性側索硬化症における運動ニューロン死の分子病態. 内科 94：952-961，2004.
  36. 郭　伸：ALSのグルタミン酸受容体異常と病因との関連について. 運動障害 14:33-41，2004.
  37. 河原行郎, 日出山拓人, 郭　伸：筋萎縮性側索硬化症の分子標的治療への展望. 最新医学 59:1620-1626，2004
  38. 河原行郎, 郭　伸：ALSにおけるRNA編集異常と脊髄運動ニューロン死. 医学の歩み　209:979-980，2004.
  39. 河原行郎, 郭　伸：脳科学におけるRNA編集の重要性. Clinical Neuroscience　22:250-251，2004.
このページの先頭へ